Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion

Guo, Mengfei; Wu, Feng; Hu, Guorong; Chen, Lian; Xu, Jing; Xu, Pingwei; Wang, Xuan; Li, Yumei; Liu, Shuqing; Zhang, Shuai; Huang, Qi; Fan, Jinshuo; Lv, Zhi; Zhou, Mei; Duan, Limin; Liao, Tingting; Yang, Guanghai; Tang, Ke; Liu, Bi‐Feng; Liao, Xiaofei; Tao, Xin; Jin, Yang

doi:10.1126/scitranslmed.aat5690

Cited by 149 publications

(84 citation statements)

References 60 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, modified or engineered EVs can be used as vaccines to provide anti-tumor immunity [88]. Previous experiments have shown that UV-exposed lung cancer TDEs are capable of promoting DC maturation and inducing T cell-dependent anti-tumor immunity, compared to normally secreted TDEs [89,90]. The DNA in TDEs was found to engage the cGAS/STING pathway and possibly be involved in the process underlying DC maturation.…”

Section: Cancer Vaccinementioning

confidence: 99%

Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications

Kato

Vykoukal

Fahrmann

et al. 2021

Cancers

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are nano-sized lipid-bound particles containing proteins, nucleic acids and metabolites released by cells. They have been identified in body fluids including blood, saliva, sputum and pleural effusions. In tumors, EVs derived from cancer and immune cells mediate intercellular communication and exchange, and can affect immunomodulatory functions. In the context of lung cancer, emerging evidence implicates EV involvement during various stages of tumor development and progression, including angiogenesis, epithelial to mesenchymal transformation, immune system suppression, metastasis and drug resistance. Additionally, tumor-derived EVs (TDEs) have potential as a liquid biopsy source and as a means of therapeutic targeting, and there is considerable interest in developing clinical applications for EVs in these contexts. In this review, we consider the biogenesis, components, biological functions and isolation methods of EVs, and the implications for their clinical utility for diagnostic and therapeutic applications in lung cancer.

show abstract

Section: Cancer Vaccinementioning

confidence: 99%

Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications

Kato

Vykoukal

Fahrmann

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…For CEVs loaded with chemotherapeutic agents, the process of irradiation was able to improve the efficacy in the cancer treatment (51). Another study showed that compared with the PBS group, CEVs of A549 lung cancer promoted the progression of cancer and malignant pleural effusion, while the irradiated CEVs group showed no significant change in the cancer progression (25). Additionally, the irradiated and drug-loaded CEVs of A549 lung cancer inhibited the progression of cancer and malignant pleural effusion in the clinical tests (25,52).…”

Section: Irradiated Cancer Cells-derived Extracellular Vesiclesmentioning

confidence: 99%

“…The injections of cisplatin-loaded CEVs were administered intrathoracically four times, and the results exhibited a 95% reduction in tumor cells in the MPE. In another clinical study with methotrexate-loaded CEVs (25), autologous tumor cells were prepared from patients' MPE and incubated with chemotherapeutic methotrexate after ultraviolet irradiation. The methotrexate-loaded CEVs were collected by ultracentrifugation.…”

Section: Chemotherapeutic Drugs Loaded Cancer Cells-derived Vesiclesmentioning

confidence: 99%

“…The specific accumulation of CEVs in the tumor area implies that CEVs could be used for drug delivery for potential targeted therapy. Thus, recent studies investigated the effects of drugloaded CEVs and found excellent effectiveness against cancer (21)(22)(23)(24)(25)(26). Additionally, oncolytic viruses can also be packed into CEVs to protect them from neutralizing antibodies in the serum, allowing them to function as oncolytic agents (27).…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, cancer cells were also irradiated to prepare CEVs to enhance the safety and anti-tumor efficacy of CEVs. With a potential role in exosome-mediated bystander effects (34), these irradiated CEVs could inhibit the progression of the tumor (25,35).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Current Strategies for Cancer Cell-Derived Extracellular Vesicles for Cancer Therapy

Lin

Cai

2021

Front. Oncol.

View full text Add to dashboard Cite

Cancer cell-derived extracellular vesicles (CEVs), a novel type of therapeutic agent in cancer treatment, can be prepared from the autocrine secretion of various cancer cells, the direct extraction of cancer cells and the combination of cancer cell-derived membranes with advanced materials. With various bioactive molecules, exosomes are produced by cells for intercellular communication. Although cancer cell-derived exosomes are known to inhibit tumor apoptosis and promote the progression of cancer, researchers have developed various innovative strategies to prepare anti-tumor vesicles from cancer cells. With current strategies for anti-tumor vesicles, four different kinds of CEVs are classified including irradiated CEVs, advanced materials combined CEVs, chemotherapeutic drugs loaded CEVs and genetically engineered CEVs. In this way, CEVs can not only be the carriers for anti-tumor drugs to the target tumor area but also act as immune-active agents. Problems raised in the strategies mainly concerned with the preparation, efficacy and application. In this review, we classified and summarized the current strategies for utilizing the anti-tumor potential of CEVs. Additionally, the challenges and the prospects of this novel agent have been discussed.

show abstract

Cancer as an infective disease: the role of EVs in tumorigenesis

et al. 2022

View full text Add to dashboard Cite

Cancer is conventionally considered an evolutionary disease where tumor cells adapt to the environment and evolve eventually leading to the formation of metastasis through the seeding and growth of metastasis-initiating cells in distant organs. Tumor cell and tumor-stroma communication via soluble factors and extracellular vesicles (EVs) are essential for the success of the metastatic process. As the field of EVs advances, growing data support the role of tumor-derived EVs not only in modifying the microenvironment to facilitate tumor progression but also in inducing changes in cells outside the primary tumor that may lead to a malignant transformation. Thus, an alternative hypothesis has emerged suggesting the conceptualization of cancer as an 'infective' disease. Still, tackling EVs as a possible cancer treatment has not been widely explored. A major understanding is needed to unveil possible additional contributions of EVs in progression and metastasis, which may be essential for the development of novel approaches to treat cancer patients. Here, we review the contribution of EVs to cancer progression and the possible implication of these factors in the oncogenic transformation of indolent cells.

show abstract

Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion

Abstract: This study investigated the application of a therapeutic tumor cell–derived microparticle-based nanodelivery platform in malignant pleural effusion.

Cited by 149 publications

References 60 publications

Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications

Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications

Current Strategies for Cancer Cell-Derived Extracellular Vesicles for Cancer Therapy

Cancer as an infective disease: the role of EVs in tumorigenesis

Contact Info

Product

Resources

About